ChemicalBook > Product Catalog >Biologics >Biochemical Reagents >Antagonist >Ramucirumab

Ramucirumab

Request For Quotation
Ramucirumab Suppliers list
Company Name: BOC Sciences
Tel: +1-631-485-4226
Email: inquiry@bocsci.com
Products Intro: Product Name:Ramucirumab
CAS:947687-13-0
Purity:>=98% Remarks:Reach out to us for more information about custom solutions.
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354; +17819995354
Email: marketing@targetmol.com
Products Intro: Product Name:Ramucirumab
CAS:947687-13-0
Purity:SDS-PAGE:98.2%;SEC-HPLC:99.2% Package:1mg;216USD|5mg;538USD|10mg;777USD Remarks:REAGENT;FOR LABORATORY USE ONLY
Company Name: Hubei Ipure Biology Co., Ltd
Tel: +8613367258412
Email: ada@ipurechemical.com
Products Intro: Product Name:Ramucirumab
CAS:947687-13-0
Purity:0.99 Package:5KG;1KG
Company Name: HONG KONG IPURE BIOLOGY CO.,LIMITED
Tel: 86 18062405514 18062405514
Email: ada@ipurechemical.com
Products Intro: Product Name:Ramucirumab
CAS:947687-13-0
Purity:.99 Package:5KG;1KG
Company Name: Shanghai Minbiotech Co., Ltd.
Tel: +8617315815539
Email: sales@minbiotech.com
Products Intro: Product Name:Ramucirumab
CAS:947687-13-0
Package:1g；1kg；10kg

Ramucirumab manufacturers

  • Ramucirumab
  • Ramucirumab pictures
  • $216.00 / 1mg
  • 2026-04-20
  • CAS:947687-13-0
  • Min. Order:
  • Purity: 99.20%
  • Supply Ability: 10g
Ramucirumab Basic information
Product Name:Ramucirumab
Synonyms:Ramucirumab;Ramucirumab,NSCLC,non–small-cell lung cancer,gastric cancer,Inhibitor,VEGFR,Vascular endothelial growth factor receptor,inhibit,angiogenesis inhibitor;Cyramza;IMC-1121B;LY3009806;Ramucirumab (anti-VEGFR2);Ramucirumab (anti-VEGFR)
CAS:947687-13-0
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Ramucirumab Structure
Ramucirumab Chemical Properties
storage temp. Store at -20°C
solubility Soluble in DMSO
form Liquid
color Colorless to light yellow
Safety Information
Hazardous Substances Data947687-13-0(Hazardous Substances Data)
MSDS Information
Ramucirumab Usage And Synthesis
Clinical UseHuman monoclonal antibody:
Treatment of advanced gastric cancer or gastrooesophageal junction adenocarcinoma, colorectal cancer and non-small cell lung cancer (NSLC)
targetVEGFR2
Drug interactionsPotentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live vaccines - avoid.
MetabolismThe metabolism of ramucirumab has not been studied. Monoclonal antibodies are mainly cleared by catabolism.
Ramucirumab Preparation Products And Raw materials
Tag:Ramucirumab(947687-13-0) Related Product Information
Rituximab Adalimumab Ustekinumab Nivolumab Bevacizumab Daratumumab Omalizumab Pembrolizumab Dulaglutide Infliximab palivizumab Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer Atezolizumab Denosumab Cetuximab Evolocumab ipilimumab Eculizumab